.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Cipla
Mallinckrodt
Dow
Deloitte
Teva
Fuji
Chinese Patent Office
Citi
Harvard Business School

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,972,990

« Back to Dashboard

Which drugs does patent 5,972,990 protect, and when does it expire?


Patent 5,972,990 protects DIOVAN and is included in one NDA. There has been one Paragraph IV challenge on Diovan.

Protection for DIOVAN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eight patent family members in eight countries.

Summary for Patent: 5,972,990

Title: Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
Abstract:The invention involves a method for treating a human survivor of a heart attack and provides further improvement in survival following the heart attack by the early initiation and long-term administration of a renin-angiotensin system inhibitor, preferably an angiotensin converting enzyme inhibitor. The inhibitor may be used on its own, or in conjunction with other therapeutic compounds such as data blockers and thrombolytic agents. The preferred inhibitor is captopril.
Inventor(s): Pfeffer; Marc A. (Chestnut Hill, MA), Pfeffer; Janice M. (Chestnut Hill, MA), Braunwald; Eugene (Weston, MA)
Assignee: Brigham and Women's Hospital, Inc. (Boston, MA)
Application Number:07/981,196
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis
DIOVAN
valsartan
TABLET;ORAL021283-004Aug 14, 2002ABRXYesNo► Subscribe► SubscribeY
Novartis
DIOVAN
valsartan
TABLET;ORAL021283-001Jul 18, 2001ABRXYesNo► Subscribe► SubscribeY
Novartis
DIOVAN
valsartan
TABLET;ORAL021283-002Jul 18, 2001ABRXYesNo► Subscribe► SubscribeY
Novartis
DIOVAN
valsartan
TABLET;ORAL021283-003Jul 18, 2001ABRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,972,990

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,952,305 Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims► Subscribe
5,977,160 Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,972,990

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia4281093► Subscribe
Canada2117782► Subscribe
Germany69333362► Subscribe
Denmark0641218► Subscribe
European Patent Office0641218► Subscribe
European Patent Office1262175► Subscribe
Spain2211867► Subscribe
JapanH07505884► Subscribe
World Intellectual Property Organization (WIPO)9320839► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Healthtrust
Argus Health
Daiichi Sankyo
Mallinckrodt
McKesson
Fish and Richardson
Chinese Patent Office
McKinsey
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot